Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC41H40F3N11O9 |
InChIKeyIMMOSWKLWDOJCE-UHFFFAOYSA-N |
CAS Registry2360530-61-4 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 29 Dec 2020 |





